;PMID: 7627947
;source_file_2911.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..184] = [t:45..184]
;2)section:[e:188..219] = [t:188..219]
;3)section:[e:223..331] = [t:223..331]
;4)sentence:[e:335..522] = [t:335..522]
;5)sentence:[e:523..694] = [t:523..694]
;6)sentence:[e:695..858] = [t:695..858]
;7)sentence:[e:859..951] = [t:859..951]
;8)sentence:[e:952..1141] = [t:952..1141]
;9)sentence:[e:1142..1233] = [t:1142..1233]
;10)sentence:[e:1234..1412] = [t:1234..1412]
;11)section:[e:1416..1460] = [t:1416..1460]

;section 0 Span:0..39
;Cancer Res.  1995 Aug 15;55(16):3471-4.
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..10] Res) (.:[10..11] .) (CD:[13..17] 1995)
        (NNP:[18..21] Aug) (CD:[22..24] 15) (CD:[24..27] ;55)
        (-LRB-:[27..28] -LRB-) (CD:[28..30] 16) (-RRB-:[30..31] -RRB-)
        (::[31..32] :) (CD:[32..39] 3471-4.)))

;sentence 1 Span:45..184
;Duplication of N-MYC at its resident site 2p24 may be a mechanism of
;activation  alternative to amplification in human neuroblastoma cells.
;[45..56]:variation-type:"Duplication"
;[60..65]:gene-rna:"N-MYC"
;[87..91]:variation-location:"2p24"
;[141..154]:variation-type:"amplification"
;[164..183]:malignancy-type:"neuroblastoma cells"
(SENT
  (S-HLN
    (NP-SBJ
      (NP (NN:[45..56] Duplication))
      (PP (IN:[57..59] of)
        (NP (NN:[60..65] N-MYC)))
      (PP-LOC (IN:[66..68] at)
        (NP (PRP$:[69..72] its) (JJ:[73..81] resident) (NN:[82..86] site)
            (NN:[87..91] 2p24))))
    (VP (MD:[92..95] may)
      (VP (VB:[96..98] be)
        (NP-PRD
          (NP
            (NP (DT:[99..100] a) (NN:[101..110] mechanism))
            (PP (IN:[111..113] of)
              (NP (NN:[114..124] activation))))
          (ADJP (JJ:[126..137] alternative)
            (PP (TO:[138..140] to)
              (NP (NN:[141..154] amplification)))))
        (PP-LOC (IN:[155..157] in)
          (NP (JJ:[158..163] human)
             (NN:[164..177] neuroblastoma) (NNS:[178..183] cells)))))
    (.:[183..184] .)))

;section 2 Span:188..219
;Corvi R, Savelyeva L, Schwab M.
(SEC
  (FRAG (NNP:[188..193] Corvi) (NNP:[194..195] R) (,:[195..196] ,)
        (NNP:[197..206] Savelyeva) (NNP:[207..209] L,) (NNP:[210..216] Schwab)
        (NNP:[217..219] M.)))

;section 3 Span:223..331
;Division of Cytogenetics-0130, Deutsches Krebsforschungszentrum, German
;Cancer  Research Center, Heidelberg.
(SEC
  (FRAG (NNP:[223..231] Division) (IN:[232..234] of)
        (NNP:[235..247] Cytogenetics) (CD:[247..252] -0130) (,:[252..253] ,)
        (NNP:[254..263] Deutsches) (NNP:[264..286] Krebsforschungszentrum)
        (,:[286..287] ,) (NNP:[288..294] German) (NNP:[295..301] Cancer)
        (NNP:[303..311] Research) (NNP:[312..318] Center) (,:[318..319] ,)
        (NNP:[320..330] Heidelberg) (.:[330..331] .)))

;sentence 4 Span:335..522
;Amplification of the human N-MYC proto-oncogene is frequently seen either in 
;extrachromosomal double minutes or in homogeneously staining regions of 
;aggressively growing neuroblastomas.
;[335..348]:variation-type:"Amplification"
;[362..367]:gene-rna:"N-MYC"
;[413..444]:variation-type:"extrachromosomal double minutes"
;[507..521]:malignancy-type:"neuroblastomas"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[335..348] Amplification))
      (PP (IN:[349..351] of)
        (NP (DT:[352..355] the) (JJ:[356..361] human) (NN:[362..367] N-MYC)
            (AFX:[368..373] proto) (HYPH:[373..374] -) (NN:[374..382] oncogene))))
    (VP (VBZ:[383..385] is)
      (ADVP (RB:[386..396] frequently))
      (VP (VBN:[397..401] seen)
        (NP-1 (-NONE-:[401..401] *))
        (PP-LOC (CC:[402..408] either)
          (PP (IN:[409..411] in)
            (NP (JJ:[413..429] extrachromosomal) (JJ:[430..436] double)
                (NNS:[437..444] minutes)))
          (CC:[445..447] or)
          (PP (IN:[448..450] in)
            (NP
              (NP
                (ADJP (RB:[451..464] homogeneously) (VBG:[465..473] staining))
                (NNS:[474..481] regions))
              (PP (IN:[482..484] of)
                (NP
                  (ADJP (RB:[486..498] aggressively) (VBG:[499..506] growing))
                  (NNS:[507..521] neuroblastomas))))))))
    (.:[521..522] .)))

;sentence 5 Span:523..694
;N-MYC maps to chromosome 2 band p23-24, but  homogeneously staining regions
;have never been observed at this band, suggesting  transposition of N-MYC
;during amplification.
;[523..528]:gene-rna:"N-MYC"
;[537..561]:variation-location:"chromosome 2 band p23-24"
;[650..663]:variation-type:"transposition"
;[667..672]:gene-rna:"N-MYC"
;[680..693]:variation-type:"amplification"
(SENT
  (S
    (S
      (NP-SBJ (NN:[523..528] N-MYC))
      (VP (VBZ:[529..533] maps)
        (PP-CLR (TO:[534..536] to)
          (NP
            (NP
              (NML (NN:[537..547] chromosome) (CD:[548..549] 2))
              (NN:[550..554] band)
              (NML-1 (NN:[555..556] p))
              (CD:[556..558] 23))
            (PP (HYPH:[558..559] -)
              (NP
                (NML-1 (-NONE-:[559..559] *P*))
                (CD:[559..561] 24)))))))
    (,:[561..562] ,) (CC:[563..566] but)
    (S
      (NP-SBJ-2
        (ADJP (RB:[568..581] homogeneously) (VBG:[582..590] staining))
        (NNS:[591..598] regions))
      (VP (VBP:[599..603] have)
        (ADVP (RB:[604..609] never))
        (VP (VBN:[610..614] been)
          (VP (VBN:[615..623] observed)
            (NP-2 (-NONE-:[623..623] *))
            (PP-LOC (IN:[624..626] at)
              (NP (DT:[627..631] this) (NN:[632..636] band)))
            (,:[636..637] ,)
            (S-ADV
              (NP-SBJ (-NONE-:[637..637] *))
              (VP (VBG:[638..648] suggesting)
                (NP
                  (NP (NN:[650..663] transposition))
                  (PP (IN:[664..666] of)
                    (NP (NN:[667..672] N-MYC)))
                  (PP-TMP (IN:[673..679] during)
                    (NP (NN:[680..693] amplification))))))))))
    (.:[693..694] .)))

;sentence 6 Span:695..858
;Previous studies had suggested that  in cells with amplified N-MYC the
;chromosomes 2 appear to be unaltered and to  carry one apparently normal copy
;of N-MYC each.
;[746..755]:variation-type:"amplified"
;[756..761]:gene-rna:"N-MYC"
;[766..779]:variation-location:"chromosomes 2"
;[847..852]:gene-rna:"N-MYC"
(SENT
  (S
    (NP-SBJ (JJ:[695..703] Previous) (NNS:[704..711] studies))
    (VP (VBD:[712..715] had)
      (VP (VBN:[716..725] suggested)
        (SBAR (IN:[726..730] that)
          (S
            (PP-LOC (IN:[732..734] in)
              (NP
                (NP (NNS:[735..740] cells))
                (PP (IN:[741..745] with)
                  (NP (VBN:[746..755] amplified) (NN:[756..761] N-MYC)))))
            (NP-SBJ-1 (DT:[762..765] the)
               (NNS:[766..777] chromosomes) (CD:[778..779] 2))
            (VP (VBP:[780..786] appear)
              (S
                (NP-SBJ-1 (-NONE-:[786..786] *))
                (VP
                  (VP (TO:[787..789] to)
                    (VP (VB:[790..792] be)
                      (ADJP-PRD (JJ:[793..802] unaltered))))
                  (CC:[803..806] and)
                  (VP (TO:[807..809] to)
                    (VP (VB:[811..816] carry)
                      (NP
                        (NP (CD:[817..820] one)
                          (ADJP (RB:[821..831] apparently)
                                (JJ:[832..838] normal))
                          (NN:[839..843] copy))
                        (PP (IN:[844..846] of)
                          (NP (NN:[847..852] N-MYC)))
                        (ADVP (RB:[853..857] each))))))))))))
    (.:[857..858] .)))

;sentence 7 Span:859..951
;In contrast, the contribution of  N-MYC to tumors which lack amplification
;has been unclear.
;[893..898]:gene-rna:"N-MYC"
(SENT
  (S
    (PP (IN:[859..861] In)
      (NP (NN:[862..870] contrast)))
    (,:[870..871] ,)
    (NP-SBJ
      (NP (DT:[872..875] the) (NN:[876..888] contribution))
      (PP (IN:[889..891] of)
        (NP (NN:[893..898] N-MYC)))
      (PP (TO:[899..901] to)
        (NP
          (NP (NNS:[902..908] tumors))
          (SBAR
            (WHNP-1 (WDT:[909..914] which))
            (S
              (NP-SBJ-1 (-NONE-:[914..914] *T*))
              (VP (VBP:[915..919] lack)
                (NP (NN:[920..933] amplification))))))))
    (VP (VBZ:[934..937] has)
      (VP (VBN:[938..942] been)
        (ADJP-PRD (JJ:[943..950] unclear))))
    (.:[950..951] .)))

;sentence 8 Span:952..1141
;We here show, by  fluorescence in situ hybridization, that N-MYC is
;occasionally duplicated at its  resident site in neuroblastoma cell lines
;previously thought to have a single  copy gene.
;[1011..1016]:gene-rna:"N-MYC"
;[1069..1082]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (PRP:[952..954] We))
    (ADVP (RB:[955..959] here))
    (VP (VBP:[960..964] show) (,:[964..965] ,)
      (PP-MNR (IN:[966..968] by)
        (NP (NN:[970..982] fluorescence)
          (NML (FW:[983..985] in) (FW:[986..990] situ))
          (NN:[991..1004] hybridization)))
      (,:[1004..1005] ,)
      (SBAR (IN:[1006..1010] that)
        (S
          (NP-SBJ-1 (NN:[1011..1016] N-MYC))
          (VP (VBZ:[1017..1019] is)
            (ADVP (RB:[1020..1032] occasionally))
            (VP (VBN:[1033..1043] duplicated)
              (NP-1 (-NONE-:[1043..1043] *))
              (PP (IN:[1044..1046] at)
                (NP (PRP$:[1047..1050] its) (JJ:[1052..1060] resident)
                    (NN:[1061..1065] site)))
              (PP-LOC (IN:[1066..1068] in)
                (NP
                  (NP (NN:[1069..1082] neuroblastoma) (NN:[1083..1087] cell)
                      (NNS:[1088..1093] lines))
                  (VP
                    (ADVP (RB:[1094..1104] previously))
                    (VBN:[1105..1112] thought)
                    (S
                      (NP-SBJ (-NONE-:[1112..1112] *))
                      (VP (TO:[1113..1115] to)
                        (VP (VB:[1116..1120] have)
                          (NP (DT:[1121..1122] a) (JJ:[1123..1129] single)
                              (NN:[1131..1135] copy) (NN:[1136..1140] gene)))))))))))))
    (.:[1140..1141] .)))

;sentence 9 Span:1142..1233
;Additionally, we detected duplication in a neuroblastoma cell line  carrying
;amplification.
;[1168..1179]:variation-type:"duplication"
;[1185..1198]:malignancy-type:"neuroblastoma"
;[1219..1232]:variation-type:"amplification"
(SENT
  (S
    (ADVP (RB:[1142..1154] Additionally))
    (,:[1154..1155] ,)
    (NP-SBJ (PRP:[1156..1158] we))
    (VP (VBD:[1159..1167] detected)
      (NP (NN:[1168..1179] duplication))
      (PP-LOC (IN:[1180..1182] in)
        (NP
          (NP (DT:[1183..1184] a) (NN:[1185..1198] neuroblastoma)
              (NN:[1199..1203] cell) (NN:[1204..1208] line))
          (VP (VBG:[1210..1218] carrying)
            (NP (NN:[1219..1232] amplification))))))
    (.:[1232..1233] .)))

;sentence 10 Span:1234..1412
;Our results raise the possibility that duplication may,  in some
;neuroblastomas, either be a prelude to amplification or an alternative 
;pathway by which N-MYC becomes activated.
;[1273..1284]:variation-type:"duplication"
;[1299..1313]:malignancy-type:"neuroblastomas"
;[1338..1351]:variation-type:"amplification"
;[1388..1393]:gene-rna:"N-MYC"
(SENT
  (S
    (NP-SBJ (PRP$:[1234..1237] Our) (NNS:[1238..1245] results))
    (VP (VBP:[1246..1251] raise)
      (NP (DT:[1252..1255] the) (NN:[1256..1267] possibility)
        (SBAR (IN:[1268..1272] that)
          (S
            (NP-SBJ (NN:[1273..1284] duplication))
            (VP (MD:[1285..1288] may) (,:[1288..1289] ,)
              (PP-LOC (IN:[1291..1293] in)
                (NP (DT:[1294..1298] some))
                (NNS:[1299..1313] neuroblastomas))
              (,:[1313..1314] ,)
              (VP (CC:[1315..1321] either) (VB:[1322..1324] be)
                (NP-PRD
                  (NP
                    (NP (DT:[1325..1326] a) (NN:[1327..1334] prelude))
                    (PP (TO:[1335..1337] to)
                      (NP (NN:[1338..1351] amplification))))
                  (CC:[1352..1354] or)
                  (NP
                    (NP (DT:[1355..1357] an) (JJ:[1358..1369] alternative)
                        (NN:[1371..1378] pathway))
                    (SBAR
                      (WHPP-1 (IN:[1379..1381] by)
                        (WHNP (WDT:[1382..1387] which)))
                      (S
                        (NP-SBJ (NN:[1388..1393] N-MYC))
                        (VP (VBZ:[1394..1401] becomes)
                          (ADJP-PRD (VBN:[1402..1411] activated))
                          (PP-1 (-NONE-:[1411..1411] *T*)))))))))))))
    (.:[1411..1412] .)))

;section 11 Span:1416..1460
;PMID: 7627947 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1416..1420] PMID) (::[1420..1421] :) (CD:[1422..1429] 7627947)
        (NN:[1430..1431] -LSB-) (NNP:[1431..1437] PubMed) (::[1438..1439] -)
        (NN:[1440..1447] indexed) (IN:[1448..1451] for)
        (NNP:[1452..1460] MEDLINE-RSB-)))
